Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing–Remitting Multiple Sclerosis Patients

Aina Teniente-Serra, José Vicente Hervás, Bibiana Quirant-Sánchez, María José Mansilla, Laia Grau-López, Cristina Ramo-Tello, Eva María Martínez-Cáceres

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

© 2016 John Wiley & Sons Ltd Aims: Fingolimod, oral treatment for relapsing–remitting multiple sclerosis (RRMS), is an agonist of sphingosine and its metabolite S1P that binds their receptors, blocking the egress of lymphocytes from lymph nodes. The aim of this study was immunomonitoring of minor peripheral lymphocyte subpopulations in RRMS patients under treatment with fingolimod and correlation with treatment response. Methods: Prospective study. T- and B-cell subpopulations were analyzed using multiparametric flow cytometry in peripheral blood from 14 RRMS patients under treatment with fingolimod at baseline, +1, +3, +6, +9, and +12 months of follow-up. Response to therapy was assessed at month +12. Results: Most changes in minor lymphocyte subpopulations occurred in the first month of treatment and were maintained until the end of follow-up. The basal percentages of recent thymic emigrants (RTEs) and transitional B cells were lower in responder patients than in nonresponders. After 1 month of follow-up, the percentages of late effector memory CD4+ T cells in peripheral blood were higher in responder patients. Conclusion: If confirmed in a bigger cohort of patients, analysis of percentages of minor lymphocyte subpopulations in peripheral blood of patients with RRMS prior and after +1 month of treatment might predict clinical response to fingolimod.
Original languageEnglish
Pages (from-to)584-592
JournalCNS Neuroscience and Therapeutics
Volume22
Issue number7
DOIs
Publication statusPublished - 1 Jul 2016

Keywords

  • Fingolimod
  • Immunomonitoring
  • Minor lymphocyte subpopulations
  • Multiple sclerosis
  • Response to treatment

Fingerprint Dive into the research topics of 'Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing–Remitting Multiple Sclerosis Patients'. Together they form a unique fingerprint.

Cite this